Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Mylan: $5 Billion Potential Liability From EpiPen Underpayment Of CMS Rebates
Mylan: $5 Billion Potential Liability From EpiPen Underpayment Of CMS Rebates
Mylan: $5 Billion Potential Liability From EpiPen Underpayment Of CMS Rebates
Submitted by
admin
on February 6, 2017 - 11:56am
Source:
Seeking Alpha
News Tags:
Mylan Labs
EpiPens
CMS
rebates
Medicare
Medicaid
Headline:
Mylan: $5 Billion Potential Liability From EpiPen Underpayment Of CMS Rebates
Do Not Allow Advertisers to Use My Personal information
